1. Pink Sheet
  2. >>Market Access

US Medicare Cost For Part D Redesign Could Far Exceed Earlier Projections, CBO Says

 
• By Cathy Kelly

Instead of $5bn in 2025, the redesign could cost the federal government two to four times that amount, the Congressional Budget Office told Republican lawmakers. And the Part D premium stabilization demonstration will cost an additional $7bn, the office projected.

CBO's Score Is An Attention Getter But $10bn Range In Forecast Underscores Uncertainty • Source: Shutterstock

Implementation the Medicare Part D redesign in 2025 could cost the federal government $10bn to $20bn more than previously projected in that year alone, the Congressional Budget Office told Republican leaders in the US House and Senate in a 2 October letter.

Key Takeaways

  • The Medicare Part D redesign established by the Inflation Reduction Act could cost the US government $10bn to $20bn in 2025, according to the Congressional Budget Office. 

The $10bn range in the projection indicates considerable uncertainty on CBO’s part, but even on the low end of the...

More from Market Access

More from Pink Sheet

EMA Explores Supporting Drug Development For High Unmet Need Disorder Scleroderma

 
• By Neena Brizmohun

While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.

EMA Nod For First MASH Drug Rezdiffra, Cell Therapy Zemcelpro And 11 Others

 
• By Eliza Slawther

Madrigal Pharmaceuticals’ Rezdiffra is on track to become the first medicine approved in the EU for non-cirrhotic metabolic dysfunction-associated steatohepatitis after the European Medicines Agency recommended that it be granted conditional marketing authorization.

BIO Notebook: Policy Uncertainty Constraining Dealmaking

 
• By Mandy Jackson and Joseph Haas

Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.